New malignancy concerns raised for Pfizer's JAK inhibitor ahead of AdCom
This article was originally published in Scrip
Executive Summary
Pfizer's experimental rheumatoid arthritis (RA) treatment tofacitinib was linked to an increased risk of solid tumour and hematologic malignancies, including lymphoproliferative disorder (LPD), indicating a potential safety signal, US drug regulators said on 7 May.